Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of …
A Kerschbaumer, A Sepriano, SA Bergstra… - Annals of the …, 2023 - ard.bmj.com
Objectives To update the evidence on efficacy of DMARDs (disease-modifying antirheumatic
drugs) and inform the taskforce of the 2022 update of the European Alliance of Associations …
drugs) and inform the taskforce of the 2022 update of the European Alliance of Associations …
The flare of rheumatic disease after SARS-CoV-2 vaccination: a review
Y Xie, Y Liu, Y Liu - Frontiers in Immunology, 2022 - frontiersin.org
As the coronavirus disease 2019 (COVID-19) pandemic continues worldwide, vaccination
has been considered an effective measure to protect people from the COVID-19 and end the …
has been considered an effective measure to protect people from the COVID-19 and end the …
2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases
AR Bass, E Chakravarty, EA Akl… - Arthritis care & …, 2023 - Wiley Online Library
Objective To provide evidence‐based recommendations on the use of vaccinations in
children and adults with rheumatic and musculoskeletal diseases (RMDs). Methods This …
children and adults with rheumatic and musculoskeletal diseases (RMDs). Methods This …
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions …
A Abhishek, RJ Boyton, N Peckham… - The Lancet …, 2022 - thelancet.com
Background Immunosuppressive treatments inhibit vaccine-induced immunity against SARS-
CoV-2. We evaluated whether a 2-week interruption of methotrexate treatment immediately …
CoV-2. We evaluated whether a 2-week interruption of methotrexate treatment immediately …
2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases
Objectives To develop EULAR recommendations for screening and prophylaxis of chronic
and opportunistic infections in patients with autoimmune inflammatory rheumatic diseases …
and opportunistic infections in patients with autoimmune inflammatory rheumatic diseases …
Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases
Objective To determine the immunogenicity of the third dose of CoronaVac vaccine in a
large population of patients with autoimmune rheumatic diseases (ARD) and the factors …
large population of patients with autoimmune rheumatic diseases (ARD) and the factors …
Effect of DMARDs on the immunogenicity of vaccines
Y van Sleen, KSM van der Geest… - Nature Reviews …, 2023 - nature.com
Vaccines are important for protecting individuals at increased risk of severe infections,
including patients undergoing DMARD therapy. However, DMARD therapy can also …
including patients undergoing DMARD therapy. However, DMARD therapy can also …
Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic …
LM Frommert, ANA de Silva, J Zernicke, V Scholz… - RMD open, 2022 - rmdopen.bmj.com
Objective The development of sufficient COVID-19 vaccines has been a big breakthrough in
fighting the global SARS-CoV-2 pandemic. However, vaccination effectiveness can be …
fighting the global SARS-CoV-2 pandemic. However, vaccination effectiveness can be …
Considerations for pharmacologic management of rheumatoid arthritis in the COVID-19 era: a narrative review
R Venkat, ZS Wallace, JA Sparks - Current Rheumatology Reports, 2023 - Springer
Abstract Purpose of Review To review the impact of disease-modifying antirheumatic drugs
(DMARDs) on COVID-19 severity and vaccine immunogenicity and to discuss COVID-19 …
(DMARDs) on COVID-19 severity and vaccine immunogenicity and to discuss COVID-19 …
Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel …
TG Skaria, A Sreeprakash, R Umesh… - The Lancet …, 2022 - thelancet.com
Background There is a necessity for an optimal COVID-19 vaccination strategy for
vulnerable population groups, including people with autoimmune inflammatory arthritis on …
vulnerable population groups, including people with autoimmune inflammatory arthritis on …